AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of…
wsj.com

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
No analyst coverage available for this stock.
Trend
+0.5% vs SMA 50 · +3.2% vs SMA 200
Momentum
Dividend per payment — last 8 periods
No institutional holdings data available.
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of…

No description available.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
CCZ◀ | $64.54 | +0.00% | $16.1B | 5.3 | -1.9% | 1589.2% | 1500 |
| $396.06 | +0.57% | $2.1T | 28.7 | +3296.8% | 4510.0% | 1500 | |
| $91.86 | +2.89% | $318.3B | 14.0 | +318.8% | 1510.7% | 1500 | |
| $131.91 | +1.13% | $306.2B | 22.6 | +586.3% | 1305.9% | 1500 | |
| $187.37 | +1.17% | $290.5B | 28.1 | +862.9% | 1745.9% | 1500 | |
| $147.85 | +3.44% | $282.1B | 21.0 | +597.3% | 2564.4% | 1500 | |
| $90.67 | +1.98% | $256.7B | 14.5 | -591.0% | 668.4% | 1500 | |
| Sector avg | — | +1.60% | — | 19.2 | +724.2% | 1984.9% | 1500 |